news-med.jpg

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Hamburg, Germany, 18 April 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive ...

Topics: Corporate, Bayer, Endometriosis, Phase I Read More